QCG
BNTC icon

Quadrant Capital Group’s Benitec Biopharma BNTC Stock Holding History

Quadrant Capital Group’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-173
Closed -$1.84K – 1427
2026
Q1 		$1.84K Hold
173
– – ﹤0.01% 2518
2025
Q4 		$2.33K Buy
+173
New +$2.39K ﹤0.01% 2497

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Quadrant Capital Group's BNTC Position: Q2 2026 in Review

Quadrant Capital Group sold out of Benitec Biopharma (BNTC) in Q2 2026, closing a stake of 173 shares — an estimated $1.84K sold.

Quadrant Capital Group first reported a position in BNTC in Q4 2025 and held it in 2 quarters. The position peaked at $2.33K in Q4 2025. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Quadrant Capital Group reported no remaining Benitec Biopharma position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 173 Benitec Biopharma shares in Q2 2026, an estimated $1.84K.
  • Quadrant Capital Group first reported a position in Benitec Biopharma in Q4 2025 and held it in 2 quarters.
  • Quadrant Capital Group's Benitec Biopharma position peaked at $2.33K in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.